Table 1.
A list of currently recruiting clinical trials including celecoxib, rofecoxib, and etoricoxib in the intervention arm.
| Intervention (Drug) | CT Phase and Identifier |
Sponsor(s) | Objective of the Study |
|---|---|---|---|
| Celecoxib | Phase 4 NCT04814355 |
Stony Brook University/Brain & Behavior Research Foundation | To assess the effect of celecoxib on neuroinflammation associated with major depressive disorder |
| Phase 2 NCT03896113 |
Cliniques universitaires Saint-Luc- Université Catholique de Louvai | To evaluate the influence of prior administration of celecoxib in endometrial cancer | |
| Phase 1 NCT04120636 |
Targeted Therapy Technologies, LLC | To determine the effect of sequestered transscleral celecoxib delivery in macular oedema and inflammatory eye disorders | |
| Phase 2 NCT04673578 |
University of British Columbia | To assess the efficacy of adjunctive celecoxib to treatment-as-usual in obsessive-compulsive disorder | |
| Phase 4 NCT04147013 |
Lawson Health Research Institute | To determine the effect of celecoxib on postoperative narcotic use, aspirin-exacerbated respiratory disease (AERD), and chronic rhinosinusitis | |
| Phase 4 NCT03645187 |
Tanta University | To evaluate the efficacy of adjunctive celecoxib therapy to cancer chemotherapy in metastatic colorectal cancer patients | |
| Phase 2 NCT03498326 |
Zhejiang University | To determine the efficacy of a combination of celecoxib and gemcitabine in the treatment of R0 resection pancreatic cancer | |
| Phase 2 NCT04786548 |
New York State Psychiatric Institute | To examine the effectiveness of celecoxib in combination with ongoing medication in the treatment of obsessive-compulsive disorder (OCD) | |
| Phase 2 NCT04162873 | University of Utah | To assess the efficacy of celecoxib adjunct to standard-of-care therapy in the treatment of patients with advanced head and neck cancer | |
| Phase 1 NCT02885974 |
Baylor College of Medicine | To determine the efficacy of celecoxib combined with cisplatin and gemcitabine in the neoadjuvant treatment of localized muscle-invasive bladder cancer | |
| Phase 2 NCT04093323 |
Roswell Park Cancer Institute | To study the combination of the polarized dendritic cell (aDC1) vaccine, celecoxib, interferon α-2, and rintatolimod in the treatment of patients with refractory HLA-A2(+) melanoma. | |
| Phase 1/2 NCT03686657 |
ARKAY Therapeutics | To determine the effect of RK-01 co-administered with celecoxib, valsartan, and metformin-HCl XR on insulin resistance | |
| Phase 1/2 NCT03926338 |
Sun Yat-sen University | To determine the effect of celecoxib combined with anti-PD-1 monoclonal antibody (mAb) in the treatment of dMMR/MSI-H phenotype resectable colorectal cancer | |
| Phase 2 NCT03026140 |
The Netherlands Cancer Institute | To assess the effectiveness of celecoxib, nivolumab, and ipilimumab in early-stage colon cancer | |
| Phase 1 NCT04081389 |
Roswell Park Cancer Institute | To determine the effect of chemokine modulation therapy (including celecoxib, recombinant interferon α-2, and rintatolimod) and standard chemotherapy administered prior to surgery in treating subjects with early-stage triple-negative breast cancer | |
| Phase 2 NCT01356290 |
Medical University of Vienna | To assess the effect of biweekly bevacizumab (i.v.) in combination with celecoxib, thalidomide, fenofibrate, etoposide, and cyclophosphamide in the treatment of recurrent, progressive medulloblastoma, and ependymoma | |
| Phase 2/3 NCT00268476 |
Medical Research Council | To assess the multiple therapeutic strategies (including a celecoxib arm) in the treatment of metastatic hormone-naïve prostate cancer | |
| Rofecoxib | Phase 3 NCT04684511 |
Tremeau Pharmaceuticals | To determine the safety and efficacy of rofecoxib (TRM-201) in subjects with haemophilic arthropathy |
| Etoricoxib | Phase 1 NCT04830579 |
Pharmtechnology LLC | To determine the bioequivalence of two formulations of etoricoxib by Pharmtechnology and Merck |
| Early Phase 1 NCT05142098 |
Dow University of Health Sciences | To compare the anti-inflammatory effect of etoricoxib and pre-emptive dexamethasone following impacted third molar surgery | |
| Phase 3 NCT04968158 |
Laboratorios Silanes S.A. de C.V. | To compare and determine the safety and efficacy of a combination of etoricoxib and tramadol compared with a combination of acetaminophen and tramadol in the treatment of acute low back pain |